Table 1.

The relationship between GPX1 genotype and breast cancer risk

GPX1 genotype, n (%)
Pro198ProPro198LeuLeu198Leu
Cases581 (47.27)515 (41.9)133 (10.82)
Controls774 (47.51)694 (42.60)161 (9.88)
OR (95% CI)*1.00 (reference)0.91 (0.77-1.07)1.07 (0.82-1.40)
1040 G/G1040 G/A1040 A/A
Cases678 (54.59)477 (38.41)87 (7.00)
Controls897 (54.63)640 (38.97)105 (6.39)
OR (95% CI)*1.00 (reference)1.01 (0.85-1.19)1.15 (0.84-1.59)
GPX1 haplotype, n (%)
G-ProA-ProG-Leu
Cases (n = 1,293)0.420.260.32
Controls (n = 1,695)0.430.260.31
OR (95% CI)*1.00 (reference)1.09 (0.83-1.44)1.00 (0.77-1.30)
  • * Estimated by unconditional logistic regression and adjusted for age, age at menopause, postmenopausal hormone use, age at menarche, weight gain since age 18 years, history of benign breast disease, and family history of breast cancer.

  • Haplotype frequencies in case and control groups as estimated via PROC HAPLOTYPE, with all haplotypes and risk factors. In the model, the haplotype A-Leu was not observed in either group.